Compare INDI & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INDI | ETON |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 784.1M | 683.7M |
| IPO Year | 2021 | 2018 |
| Metric | INDI | ETON |
|---|---|---|
| Price | $3.40 | $25.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $6.25 | ★ $39.33 |
| AVG Volume (30 Days) | ★ 3.3M | 463.2K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.95 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $217,394,000.00 | $79,950,000.00 |
| Revenue This Year | $25.54 | $40.90 |
| Revenue Next Year | $38.45 | $47.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 0.33 | ★ 104.94 |
| 52 Week Low | $1.81 | $13.09 |
| 52 Week High | $6.05 | $27.29 |
| Indicator | INDI | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 63.48 | 58.77 |
| Support Level | $3.18 | $16.38 |
| Resistance Level | $4.77 | N/A |
| Average True Range (ATR) | 0.22 | 1.20 |
| MACD | 0.07 | -0.29 |
| Stochastic Oscillator | 90.00 | 52.03 |
Indie Semiconductor Inc is empowering the Autotech revolution with next-generation automotive semiconductors and software platforms. It focuses on edge sensors for Driver Assistance Systems including LiDAR, connected car, user experience, and electrification applications. These technologies represent the core underpinnings of both electric and autonomous vehicles, while the user interfaces transform the in-cabin experience to mirror and seamlessly connect to the mobile platforms. Geographically, the company generates majority of its revenue from Greater China and rest from United States, Europe, South Korea and other regions.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.